Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union
• Following a positive opinion from the EMA, the transfer of marketing authorization of Jyseleca from Galapagos NV to Alfasigma S.p.A has been approved by the European Commission.
• Alfasigma S.p.A. is responsible for providing filgotinib in Rheumatoid Arthritis and Ulcerative Colitis to patients in the European Union.